2005
DOI: 10.1159/000083223
|View full text |Cite
|
Sign up to set email alerts
|

Effective Treatment of Indolent Non-Hodgkin’s Lymphomas with Mitoxantrone, Chlorambucil and Prednisone

Abstract: Since indolent non-Hodgkin’s lymphomas (NHL) represent about 35% of all malignant lymphomas and mainly affect elderly patients, availability of a conventional chemotherapy regimen with high efficacy and low toxicity is of clinical importance. Patients and Methods: We retrospectively analysed 13 patients with advanced indolent NHL who were treated with 6-9 cycles of MCP: mitoxantrone 8 mg/m2 (days 1 and 2), chlorambucil 3 × 3 mg/m2 (days 1-5) and prednisone 25 mg (days 1-5) every 4 weeks. Results: The overall r… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
9
0

Year Published

2005
2005
2021
2021

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 12 publications
(9 citation statements)
references
References 30 publications
0
9
0
Order By: Relevance
“…In order to treat our patient with the lowest possible risk and side effects, we decided to use chlorambucil and prednisone. We avoided more aggressive therapies, such as fludarabine, or combination chemotherapies, such as CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) or FC (fludabarine, cyclophosphamide) [21,23]. Treatment with chlorambucil and prednisone was successful.…”
Section: Discussionmentioning
confidence: 99%
“…In order to treat our patient with the lowest possible risk and side effects, we decided to use chlorambucil and prednisone. We avoided more aggressive therapies, such as fludarabine, or combination chemotherapies, such as CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) or FC (fludabarine, cyclophosphamide) [21,23]. Treatment with chlorambucil and prednisone was successful.…”
Section: Discussionmentioning
confidence: 99%
“…CHB is used as treatment for chronic lymphatic leukemia and other clinical applications such as Hodking's and non-Hodking's lymphoma (Wohrer et al, 2005). Although it has a high therapeutic activity, CHB is a potential human carcinogen with increasing risk towards the development of secondary cancer in patients (Neugut and Ulpric, 2008).…”
Section: Introductionmentioning
confidence: 99%
“…Very recent data of randomized trials with patients with follicular lymphoma demonstrate the combination of chemotherapy and rituximab to be superior to chemotherapy alone in terms of response rates and time to treatment failure [4,5]. Due to hematological and non-hematological side effects especially in elderly patients with co-morbidities, treatment options with reduced toxicity are required [6], and rituximab monotherapy may be an interesting alternative to chemotherapy. 2 trials investigating rituximab as a single-agent treatment in chemotherapy-naive low-grade lymphoma revealed response rates of 72-80% [7,8].…”
Section: Introductionmentioning
confidence: 99%